HCW Biologics Inc. (NASDAQ:HCWB) Short Interest Update

HCW Biologics Inc. (NASDAQ:HCWB) was the recipient of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 543,700 shares, a decline of 34.9% from the February 13th total of 835,500 shares. Based on an average trading volume of 5,830,000 shares, the short-interest ratio is presently 0.1 days. Approximately 2.1% of the shares of the company are sold short.

HCW Biologics Price Performance

Shares of NASDAQ:HCWB traded down $0.00 on Monday, reaching $0.34. The company’s stock had a trading volume of 86,601 shares, compared to its average volume of 3,894,991. The stock’s 50-day moving average is $0.38 and its two-hundred day moving average is $0.46. HCW Biologics has a 52-week low of $0.21 and a 52-week high of $2.52. The stock has a market capitalization of $15.10 million, a P/E ratio of -0.34 and a beta of 0.71.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.